In head-to-head randomised controlled trials (RCTs) of patients with T2DM, insulin glargine and NPH insulin resulted in similar glycaemic control (including HbA1c), although insulin glargine was associated with a significantly reduced risk of hypoglycaemia compared with NPH insulin (11–13). This evidence concerns the gene INS and type 2 diabetes mellitus.